Skip to main content

Sickle Cell Disease and cannabis in Kentucky

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
30-day supply as certif…
POSSESSION
$25/yr
STATE FEE
14–45 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Kentucky statute and program

The Kentucky Medical Cannabis Program is the operating authority for Kentucky patient certification. The authoritative legal text is: KRS Chapter 218B: Medical Cannabis (SB 47 of 2023).

What the evidence says about cannabis and Sickle Cell Disease

Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by mutations in the hemoglobin gene. Red cells assume a rigid sickle shape under low-oxygen conditions, leading to chronic hemolytic anemia, episodic vaso-occlusive pain crises, stroke risk, acute chest syndrome, and progressive end-organ damage. SCD disproportionately affects people of African, Mediterranean, and South Asian descent.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Sickle Cell Disease page.

How to qualify in Kentucky

The Kentucky Medical Cannabis Program requires the following registration steps for a Sickle Cell Disease patient (or any qualifying diagnosis):

  1. See a Kentucky-licensed medical cannabis practitioner. Under SB 47 (2023), a Kentucky-licensed physician, advanced practice registered nurse, physician assistant, or optometrist who has completed the Kentucky Cabinet for Health and Family Services medical cannabis practitioner course and registered with the Office of Medical Cannabis may certify a patient. Qualifying conditions include any cancer, chronic, severe, intractable, or debilitating pain, epilepsy or other intractable seizure disorder, MS, muscle spasms or spasticity, chronic nausea or cyclical vomiting, and PTSD (KRS 218B.015).
  2. Apply through the Office of Medical Cannabis patient portal. The patient creates an account in the Kentucky Office of Medical Cannabis (OMC) registry portal. The certifying practitioner submits the written certification electronically; the patient then completes the patient registration with a Kentucky driver license or state ID and a passport-style photograph.
  3. Pay the state registration fee. The Kentucky medical cannabis patient registry card fee is $25 annually (caregiver registration is also $25 with a separate background check). Fees are paid online through the OMC portal. The program launched January 1, 2025; patients should expect rule updates during the program’s first operating year.
  4. Receive the card and purchase from a Kentucky dispensary. Kentucky medical cannabis registry cards are issued within roughly 30 days of complete application. Patients may purchase up to a 30-day supply from any licensed Kentucky medical cannabis dispensary. Kentucky does not authorize raw plant material for smoking; permitted forms include edibles, capsules, tinctures, vape products, topicals, and concentrates. Kentucky does not honor out-of-state medical cards.
State registration fee
$25
Physician visit (typical)
$200–$350
Certification to card
14–45 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Kentucky registration steps, fees, and reciprocity rules, see the Kentucky cannabis-laws page.

ICD-10 code

A certifying physician documenting Sickle Cell Disease for the Kentucky medical cannabis program will typically record ICD-10 D57.1 or SNOMED-CT 417357006 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Kentucky list Sickle Cell Disease as a qualifying condition for medical cannabis?

No. Kentucky's qualifying-condition list does not currently include Sickle Cell Disease, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Sickle Cell Disease in Kentucky have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Kentucky program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Kentucky medical marijuana card for Sickle Cell Disease?

Because Kentucky does not currently list Sickle Cell Disease as a qualifying condition, a card for Sickle Cell Disease alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Kentucky who is registered with Kentucky Medical Cannabis Program and willing to evaluate Sickle Cell Disease cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Kentucky does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Sickle Cell Disease?

For Sickle Cell Disease, evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Sickle Cell Disease lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Sickle Cell Disease should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Sickle Cell Disease and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Sickle Cell Disease; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. KRS Chapter 218B: Medical Cannabis (SB 47 of 2023)accessed May 16, 2026
  2. Kentucky Cabinet for Health and Family Services: Medical Cannabisaccessed May 16, 2026
  3. Wikipedia: Cannabis in Kentuckyaccessed May 16, 2026
  4. KRS Chapter 218A: Kentucky Controlled Substances Act (possession penalty schedule)accessed May 17, 2026
  5. Kentucky Department of Agriculture: Industrial Hemp Programaccessed May 17, 2026
  6. Kentucky General Assembly bill trackeraccessed May 17, 2026
  7. NIH National Heart, Lung, and Blood Institute: Sickle Cell Diseaseaccessed May 15, 2026
  8. NIH NCCIH: Cannabis (Marijuana) and Cannabinoidsaccessed May 15, 2026